Skip Navigation LinksHome > What is Xelma > Pre-clinical data

Pre-clinical data

Pre-clinical studies demonstrated that amelogenin treatment significantly increases fibroblast expression of vascular endothelial growth factor (VEGF), a growth factor that plays an important role in wound healing.

Fibroblast expression of VEGF increases after amelogenin treatment in-vitro.

Mirastschijski U et al. 2004

Pre-clinical studies demonstrated that amelogenin treatment significantly increases cell proliferation after six days.

Almqvist et al. 2009


Picture missing

A novel treatment

Xelma® is a novel treatment for hard-to-heal wounds without clinical signs of infection such as venous leg ulcers, diabetic foot ulcers and pressure ulcers.
Picture missing

What is the extracellular matrix?

The extracellular matrix (ECM) plays and important role in the wound healing process. It acts as a scaffold within the wound, providing a framework to which cells can attach, proliferate and synthesise...
Picture missing

How to use Xelma

Xelma is indicated for hard-to-heal ulcers - primarliy, venous leg ulcers. Xelma can be used under compression therapy.
Build: 1.0.1.1 (9/18/2009 12:15:54 AM)